234 related articles for article (PubMed ID: 25378232)
1. B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1.
Choi YW; Kim HJ; Kim YH; Park SH; Chwae YJ; Lee J; Soh EY; Kim JH; Park TJ
Exp Mol Med; 2014 Nov; 46(11):e120. PubMed ID: 25378232
[TBL] [Abstract][Full Text] [Related]
2. TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.
Kim YH; Choi YW; Han JH; Lee J; Soh EY; Park SH; Kim JH; Park TJ
Neoplasia; 2014 Dec; 16(12):1107-20. PubMed ID: 25499223
[TBL] [Abstract][Full Text] [Related]
3. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
4. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells.
Kogai T; Hershman JM; Motomura K; Endo T; Onaya T; Brent GA
Endocrinology; 2001 Aug; 142(8):3369-79. PubMed ID: 11459780
[TBL] [Abstract][Full Text] [Related]
7. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
[TBL] [Abstract][Full Text] [Related]
8. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
[TBL] [Abstract][Full Text] [Related]
9. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors.
Galrão AL; Camargo RY; Friguglietti CU; Moraes L; Cerutti JM; Serrano-Nascimento C; Suzuki MF; Medeiros-Neto G; Rubio IG
J Clin Endocrinol Metab; 2014 Jun; 99(6):E944-52. PubMed ID: 24432988
[TBL] [Abstract][Full Text] [Related]
11. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
12. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules.
Neumann S; Schuchardt K; Reske A; Reske A; Emmrich P; Paschke R
Thyroid; 2004 Feb; 14(2):99-111. PubMed ID: 15068624
[TBL] [Abstract][Full Text] [Related]
13. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
14. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
15. FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway.
Ma S; Wang Q; Ma X; Wu L; Guo F; Ji H; Liu F; Zhao Y; Qin G
Tumour Biol; 2016 Jan; 37(1):989-98. PubMed ID: 26264613
[TBL] [Abstract][Full Text] [Related]
16. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
17. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
18. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
19. Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray.
Gol Choe J; Kim YR; Kim KN; Choo HJ; Shin JH; Lee YJ; Chung JK; Kim MK
Nucl Med Commun; 2005 Dec; 26(12):1155-62. PubMed ID: 16264365
[TBL] [Abstract][Full Text] [Related]
20. Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression.
Galrão AL; Sodré AK; Camargo RY; Friguglietti CU; Kulcsar MA; Lima EU; Medeiros-Neto G; Rubio IG
Endocrine; 2013 Feb; 43(1):225-9. PubMed ID: 22945693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
